Compare Lufax Holding Ltd (LU) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs McKesson Corporation — how do they compare? Lufax Holding Ltd trades at $0.98 (market cap $982.89M), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 110.3× Lufax Holding Ltd's market cap, and McKesson Corporation pays a 0.4% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and McKesson Corporation for 74 Days on average.
| LU | MCK | |
|---|---|---|
Market Cap | $982.89M | $108.46B |
Volume | 3,323,384 | 712,607 |
Sector | Financials | Health |
52-Week High | $3.93 | $995.69 |
52-Week Low | $0.95 | $725.17 |
Typical Hold Time | 13 Days | 74 Days |
Enterprise Value | $58.81B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LU trades at $0.98, down 0.11% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of $2.10 billion on $23.11 billion revenue in 2025, with negative profit margins and ROE. Recent corporate actions include a 10:1 reverse stock split effective October 23, 2026. Analyst consensus remains positive with 69% buy ratings, though earnings have consistently missed expectations.
LU presents a deep value opportunity with P/S of 0.25 and P/B of 0.07, but faces significant execution risks amid declining revenue and persistent losses. The company's strong parent backing from Ping An and improving operational cash flow provide some stability, but regulatory headwinds in China's consumer lending market remain a concern for sustained recovery.
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
